GRANULESGranules India Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why buy
- • Revenue growth: 22.0% YoY
- • Profit growth: 53.4% YoY
- • Debt/Equity: 0.30
- • RSI: 67
- • MACD: bullish
- • Price vs EMA21: above
- • Bollinger Squeeze signal (setup quality 60%)
- • Bull Flag signal (setup quality 63%)
Bull case
- • Revenue growth: 22.0% YoY
- • Profit growth: 53.4% YoY
- • Debt/Equity: 0.30
- • RSI: 67
Bear case
- • Dividend yield: 0.18%
- • Beta: 0.06
Key risks
- • Dividend yield: 0.18%
- • Beta: 0.06
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹26.65). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.